The features of pathogenesis of urolithiasis in patients with diabetes mellitus type 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. In recent years, a large number of studies has been published that proved a very significant role of diabetes mellitus type 2 for development of urolithiasis. The aim of our work was to conduct a comparative study of biochemical parameters of blood and urine as well as chemical composition of urinary stones in urolithiasis patients in the general population and in patients with diabetes mellitus type 2. Materials and methods. The work was divided into 2 stages. During the first stage an analysis of chemical composition of urinary stones in the general population (n=5669) and in patients with diabetes mellitus type 2 was carried out (n=350). During the second stage an analysis of biochemical parameters of blood and urine in urolithiasis patients in the general population (n=101) and in patients with diabetes mellitus type 2 was conducted (n=350). Results. In the general population calcium oxalate stones was predominated (56.8%), while phosphate (24.9%) and urate (17.4%) stones were less frequent. In a subgroup of patients with diabetes mellitus type 2 uric acid stones were predominated (74.3%), significantly exceeding calcium oxalate (15.1%) and calcium phosphate (10.6%) stones. In the general population of patients with urolithiasis, hypercalciuria, hyperuricosuria, hyperuricemia and hypomagnesiuria was detected in 60.4%, 42.6%, 26.7% and 43.5% of cases, respectively. In patients with concomitant diabetes mellitus type 2, hypercalciuria, hyperuricosuria, hyperuricemia was observed in 9.4%, 26.7% and 42.5%, respectively. In 60.3% of patients with diabetes mellitus type 2 marked acidity of the morning urine was detected (pH<6.0). Conclusion. Correction of metabolic disorders in patients with urinary stone disease and diabetes mellitus type 2 should be aimed at increasing of urine pH and reducing the level of uric acid in the blood and urine.

Full Text

Restricted Access

About the authors

M. Yu Prosiannikov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Email: prosyannikov@gmaiI.com
PhD, Head of Department of urolithiasis

E. K Yanenko

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, professor, leading researcher, organizational and methodical Department

S. K Yarovoy

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, Leading Researcher, clinical pharmacologist

S. A Golovanov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, head of group of clinical and laboratory diagnostic of Scientific and Laboratory Department

O. V Konstantinova

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, Chief Researcher at the Department of urolithiasis

N. V Anokhin

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

PhD, junior researcher at the Department of urolithiasis

O. V Djalilov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

PhD student

A. V Sivkov

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

Email: uroinfo@yandex.ru
PhD, assistant director

O. I Apolikhin

N.A. Lopatkin Scientific Research Institute of Urology and Interventional Radiology - Branch of the National Medical Research Centre of Radiology of the Ministry of Health of Russian Federation

MD, professor, corresponding member of the Russian Academy of Sciences. Director

References

  1. Harrison M. Urinary Stone Inhibitors. M. Harrison, M. Abrahams, V. Maxwell Meng, L. Marshall Stoller. Urinary stone disease New Jersey. 2007. Р. 157-175.
  2. Ramello A., Vitale C., Marangella M. Epidemiology of nephrolithiasis. J. Nephrol. 2000;13(3):45-50.
  3. Prezioso D., Illiano E., Piccinocchi G., Cricelli C., Piccinocchi R. Urolithiasis in Italy: an epidemiological study. Arch. Ital. Urol. Androl. 2014;86(2):99-102. doi: 10.4081/aiua.2014.2.99.
  4. Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за период 2002-2014 гг. по данным официальной статистики Экспериментальная и клиническая урология. 2016;3:4-13
  5. Morgan M.S., Pearle M.S. Medicalmanagementofrenalstones. BMJ. 2016;14:352. doi: 10.1136/bmj.i52.
  6. Заболеваемость населения России в 2003 году: Статистические материалы. Часть 1. М., 2004 г. С. 215. Заболеваемость населения Российской Федерации в 2013 году: Статистические материалы [электронная версия] МЗ РФ и ЦНИИ организации и информатизации здравоохранения МЗ РФ. М., 2014
  7. Madore F., Stampfer M.J., Rimm E.B., Curhan G.C. Nephrolithiasis and risk of hypertension. Am J. Hypertens. 1998;11(1 Pt 1):46-53.
  8. Taylor E.N., Stampfer M.J., Curhan G.C. Obesity, weight gain, and the risk of kidney stones. JAMA. 2005;293(4):455-462.
  9. Taylor E.N., Stampfer M.J., Curhan G.C. Diabetes mellitus and the risk of nephrolithiasis Kidney Int. 2005;68(3):1230-1235.
  10. Rule A.D., Roger V.L., Melton L.J. 3rd, et al. Kidney stones associate with increased risk for myocardial infarction.J. Am SocNephrol. 2010;21(10):1641-1644. doi: 10.1681/ASN.2010030253.
  11. Ferraro P.M., Taylor E.N., Eisner B.H., et al. History of kidney stones and the risk of coronary heart disease. JAMA. 2013;310(4):408-15. doi: 10.1001/jama.2013.8780.
  12. Alexander R.T., Hemmelgarn B.R., Wiebe N., Bello A., Samuel S., Klarenbach S.W. et al. Kidney Stones and Cardiovascular Events: A Cohort Study. Clin J. Am SocNephrol. 2014;9(3):506-512. Doi: 10.2215/ CJN.04960513.
  13. Константинова О.В., Дзеранов Н.К. Сопутствующие заболевания у пациентов с мочекаменной болезнью. Тезисы докл. II урологической конференции «Актуальные вопросы урологии». М., 2010:94
  14. Daudon M., Jungers P. Diabetes and nephrolithiasis. Curr Diab Rep. 2007;7(6):443-448.
  15. Golden S.H., Robinson K.A., Saldanha I., Anton B., Ladenson P.W. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J. Clin Endocrinol Metab. 2009;94(6):1853-1878. doi: 10.1210/jc.2008-2291.
  16. Spatola L., Angelini C., Badalamenti S., Maringhini S., Gambaro G. Kidney stones diseases and glycaemic statuses: focus on the latest clinical evidences. Urolithiasis. 2017;45(5):457-460. doi: 10.1007/s00240-016-0956-8.
  17. West B., Luke A., Durazo-Arvizu R.A., Cao G., Shoham D., Kramer H. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988-1994. Am J. Kidney Dis. 2008;51(5):741-747. Doi: 10.1053/j. ajkd.2007.12.030.
  18. Rendina D., DeFilippo G., D’Elia L., Strazzullo P. Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. J. Nephro I. 2014;27(4):371-376. doi: 10.1007/s40620-014-0085-9.
  19. Haymann J.P. Metabolic disorders: stones as first clinical manifestation of significant diseases World J. Urol 2015;33(2):187-192. Doi: 10.1007/ s00345-014-1391-5.
  20. Голованов С.А., Сивков А.В., Анохин Н.В., Дрожжева В.В. Тенденции распространенности метаболических типов мочекаменной болезни в Московском регионе. Сравнительный анализ за период с 2010 по 2013 гг. Экспериментальная и клиническая урология. 2014;4:54-58
  21. Lieske J.C., Rule A. D., Krambeck A. E., Williams J.C., Bergstralh E.J., Mehta RA. Stone composition as a function of age and sex. Clin J. Am SocNephrol. 2014;9(12):2141-2146. doi: 10.2215/CJN.05660614.
  22. Pearle M.S., Lotan Y. Urinary lithiasis: etiology, epidemiology and pathogenesis. CampbeII-WaIsh UroIogy, ninth edition. AIan J. Wein. PhiIadeIphia, PA, 2007;2:1363-1392.
  23. Аполихин О.И., Калинченко С.Ю., Камалов А.А., Гусакова Д.А., Ефремов Е.А. Мочекаменная болезнь как новый компонент метаболического синдрома. Саратовский научно-медицинский журнал. 2011;7:117
  24. PakC.Y., Sakhaee K., Moe O., Preminger G.M., Poindexter J.R., Peterson R.D. Biochemical profile of stone-forming patients with diabetes mellitus. UroIogy. 2003;61(3):523-527.
  25. Daudon M., Traxer O., Conort P., Lacour B., Jungers P. Type 2 di betes increases the risk for uric acid stones. J. Am SocNephrol. 2006;17(7):2026-2033.
  26. Hess B. Metabolic syndrome, obesity and kidney stones. Arab J. Urol. 2012;10(3):258-264. doi: 10.1016/j.aju.2012.04.005.
  27. Chobanian M.C., Hammerman M.R. Insulin stimulates ammoniagenesis in caninerenaI proximaI tubuIar segments. Am J. Physio I. 1987;253(6 Pt 2):1171-1177.
  28. Klisic J., Hu M.C., Nief V., Reyes L., Fuster D., Moe O.W. et al. InsuIin activates the Na/H. exchanger 3 (NHE3): biphasic response and gIucocorticoid-dependence. Am J. PhysioI RenaI Physio I. 2002;283(3):F532-539.
  29. Evan A.P., Lingeman J.E., McAteer J.A., Williams J.C. Jr. Introduction to speciaI issue on the Proceedings of the 3rd InternationaI UroIithiasis Research Symposium heId in IndianapoIis. UroI Res. 2010;38(4):237. doi: 10.1007/s00240-010-0301-6.
  30. Bartoletti R., Cai T., Mondaini N., Melone F., Travaglini F., Carini M., Rizzo M. EpidemioIogy and risk factors in uroIithiasis. UroIInt. 2007;79(1):3-7.
  31. Spero D. Diabetes and Kidney Stones. Published July 22, 2015 (https:// www.diabetesseIfmanagement.com/bIog/diabetes-and-kidney-stones).
  32. Torricelli F.C., De S., Gebreselassie S., Li I., Sarkissian C., Monga M. Type-2 diabetes and kidney stones: impact of diabetes medications and glycemic control. Urology. 2014;84(3):544-548. Doi: 10.1016/j. uroIogy.2014.02.074.
  33. Голованов С.А., Сивков А.В., Дрожжева В.В., Анохин Н.В. Метаболические факторы риска и формирование мочевых камней. Исследование I: влияние кальцийурии и урикурии. Экспериментальная и клиническая урология. 2017;1:52-57
  34. Li P., Zhang L., Zhang M., Zhou C., Lin N. Uric acid enhances PKC-dependent eNOS phosphorylation and mediates cellular ER stress: A mechanism for uric acid-induced endotheIiaI dysfunction Int J. MoI Med. 2016;37(4):989-997. doi: 10.3892/ijmm.2016.2491.
  35. Wong P., Fuller P.J., Gillespie M.T., Kartsogiannis V., Strauss B.J., Bowden D., Milat F. Thalassemia bone disease: the association between nephroIithiasis, bone mineraI density and fractures Osteoporos Int. 2013I;24(7):1965-1971. doi: 10.1007/s00198-012-2260-y.
  36. Weinberg A.E., Patel C.J., Chertow G.M., Leppert J.T. Diabetic severity and risk of kidney stone disease Eur Urol. 2014;65(1):242-247. doi: 10.1016/j.eururo.2013.03.026.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies